| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:2401271 | IVR | 200 mg/L | 200 mg/L | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/L | 20 mg/L | Hyperplasia in ovary | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/L | 20 mg/L | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/L | 20 mg/L | Hepatocellular hemangioma | Endocrine-mediated cancer;Hepatic endocrine-mediated perturbations | |
| IVR | 20 mg/L | 20 mg/L | Hematopietic carcinoma | Endocrine-mediated cancer;Immunological endocrine-mediated perturbations | |
| IVR | 20 mg/L | 20 mg/L | Hepatocellular carcinoma | Endocrine-mediated cancer;Hepatic endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Hepatocellular carcinoma | Endocrine-mediated cancer;Hepatic endocrine-mediated perturbations | |
| IVR | 62.5 mg/L | 62.5 mg/L | Hematopietic carcinoma | Endocrine-mediated cancer;Immunological endocrine-mediated perturbations | |
| IVR | 625 mg/L | 625 mg/L | Hepatocellular carcinoma | Endocrine-mediated cancer;Hepatic endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Hematopietic carcinoma | Endocrine-mediated cancer;Immunological endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Hepatocellular hemangioma | Endocrine-mediated cancer;Hepatic endocrine-mediated perturbations | |
| IVR | 62.5 mg/L | 62.5 mg/L | Hyperplasia in ovary | Reproductive endocrine-mediated perturbations | |
| IVR | 625 mg/L | 625 mg/L | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 625 mg/L | 625 mg/L | Hematopietic carcinoma | Endocrine-mediated cancer;Immunological endocrine-mediated perturbations | |
| IVR | 62.5 mg/L | 62.5 mg/L | Hepatocellular hemangioma | Endocrine-mediated cancer;Hepatic endocrine-mediated perturbations | |
| IVR | 62.5 mg/L | 62.5 mg/L | Occurrence of mammary gland tumor | Endocrine-mediated can | |
| IVR | 62.5 mg/L | 62.5 mg/L | Hepatocellular carcinoma | ||
| IVR | 625 mg/L | 625 mg/L | Hyperplasia in ovary | ||
| IVR | 625 mg/L | 625 mg/L | Hepatocellular hemangioma | ||
| IVR | 200 mg/L | 200 mg/L | Hyperplasia in ovary | ||
| IVR | 6.25 mg/L | 6.25 mg/L | Hepatocellular hemangioma | ||
| IVR | 6.25 mg/L | 6.25 mg/L | Hepatocellular carcinoma | ||
| IVR | 6.25 mg/L | 6.25 mg/L | Occurrence of mammary gland tumor | ||
| IVR | 6.25 mg/L | 6.25 mg/L | Hyperplasia in ovary | ||
| IVR | 6.25 mg/L | 6.25 mg/L | Hematopietic carcinoma | ||
| PMID:3591659 | IVR | 8000 mg/L | 8000 mg/L | Increased spleen weights | Immunological endocrine-mediated perturbations |
| IVR | 8000 mg/L | 8000 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 1000 mg/L | 1000 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.